Obiettivo
TransQST will develop a Quantitative Systems Toxicology (QST) approach, employing pre-existing data where possible, in order to yield new mechanistic insight into drug-induced toxicity. A central tenet of our programme will be to ensure the human physiological and pharmacological relevance of any test system that has been (or will be) used for generating the input data for modelling. By adopting this approach, we will be able to accurately interpret what happens when test systems are perturbed by drug exposure, and ensure translatability of modelling tools. Mechanistic translational biomarkers are a core aspect of our approach and will be applied in parallel with evidence for understanding how to develop, model and apply such biomarkers in a QST setting. The project is structured in 8 work packages to provide the following outcomes: curate the best available experimental data suitable for modelling adverse drug reactions; provide fit-for-purpose QST models that will address key toxicity measures for liver, kidney, heart and GI-tract; provide quantitative risk assessment for off-target toxicity in man based on in vitro and in vivo models; provide a quantitative mechanistic read-across from species (in vivo and in vitro) currently used for the toxicological evaluation of a new drug; provide definition and applicability of the human physiological relevance of preclinical test systems; provide a battery of translational biomarkers that can be used for quantitative read-across from in vitro systems to man and which relate to intracellular pathways (and systems) relevant to drug toxicity. Led by the University of Liverpool, TransQST brings together 14 partners, characterized by their scientific rigour and proven track record. Collectively they will enable achievement of the goals of the call, thanks to their complementarity, proven ability to work together (and with EFPIA partners), and their understanding of how to ensure the relevance of QST to human biology.
Campo scientifico
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- medical and health sciencesbasic medicinepharmacology and pharmacydrug safety
- medical and health sciencesclinical medicinecardiologycardiovascular diseasescardiac arrhythmia
- medical and health sciencesbasic medicinepharmacology and pharmacyadverse drug reactions
- medical and health sciencesbasic medicinetoxicology
Parole chiave
Programma(i)
Meccanismo di finanziamento
RIA - Research and Innovation actionCoordinatore
L69 7ZX Liverpool
Regno Unito
Mostra sulla mappa
Partecipanti (23)
2311 EZ Leiden
Mostra sulla mappa
08003 Barcelona
Mostra sulla mappa
28006 Madrid
Mostra sulla mappa
L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione.
6200 MD Maastricht
Mostra sulla mappa
69117 Heidelberg
Mostra sulla mappa
OX1 2JD Oxford
Mostra sulla mappa
EC2Y 5EB London
Mostra sulla mappa
1010 Wien
Mostra sulla mappa
Partecipazione conclusa
52074 Aachen
Mostra sulla mappa
44139 Dortmund
Mostra sulla mappa
3512 KC Utrecht
Mostra sulla mappa
3015 GD Rotterdam
Mostra sulla mappa
65205 Wiesbaden
Mostra sulla mappa
RG21 4FA Basingstoke
Mostra sulla mappa
94250 GENTILLY
Mostra sulla mappa
151 85 Sodertaelje
Mostra sulla mappa
TW89GS Brentford
Mostra sulla mappa
92284 Courbevoie
Mostra sulla mappa
2340 Beerse
Mostra sulla mappa
02200 Espoo
Mostra sulla mappa
55218 Ingelheim
Mostra sulla mappa
69120 Heidelberg
Mostra sulla mappa
W2 6BD London
Mostra sulla mappa